ViatrisRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
| Period | New product revenue ($M) |
|---|---|
| Q2 2026 | 101 |
| 1H 2026 | 172 |
| FY 2026 guide (range midpoint not printed) | 450 to 550 |
| Item | Printed status | Note |
|---|---|---|
| Gwyn Lo | U.S. FDA approval in the quarter | Named as a key pipeline milestone in the Q2 release |
| Accord Healthcare (France) | Distribution agreement for filgrastim, ustekinumab, and teriparatide biosimilars | Uses Viatris regional commercial capacity after the Biocon biosimilars sale |
| Quviviq (Idorsia) | Co-promotion in Italy and Canada | Sleep franchise add-on |
| Biocon stake and non-compete | Equity sold July 14, 2026 for about $380 million pre-tax | Ex-U.S. biosimilar non-compete already expired; U.S. expires November 2026 |